07/28/2025 02:00
AGC’s Group Company in Southeast Asia Obtains International Sustainability and Carbon Certification, “ISCC PLUS Certification”

AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) (TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, has announced that its group company PT Asahimas Chemical (ASC, Headquarters: Indonesia), has recently obtained ISCC PLUS Certification*, one of the international certification systems for sustainable products. This certification confirms that biomass-derived raw materials and renewable raw materials (including those derived from renewable...

07/31/2025 08:56
Omdia: LTPS TFT and OLED Display Revenues to Exceed 50% of Automotive Display Market in 2025

According to the latest analysis from Omdia’s Automotive Display Intelligence Service, the global automotive display market is set to see strong growth in 2025 with display panel revenues projected to reach $13.6 billion, an 8% year-over-year (YoY) increase. Omdia further forecasts that the market will grow to $18.3 billion by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730996518/en/Automotive display revenues by display...

08/01/2025 09:05
San’an and Inari to Acquire 100% of Lumileds Holding B.V.’s Shares

San’an Optoelectronics and Inari Amertron Berhad today announced they have entered into a definitive agreement to acquire Lumileds Holding B.V. and its European and Asian subsidiaries (“Lumileds International”). “This transaction is the next step of our ongoing transformation. As the LED industry evolves and continues to mature, I am confident that Lumileds International will continue to be successful and accelerate its growth under the new ownership,” said Steve Barlow, CEO of Lumileds Inter...

07/28/2025 05:00
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company’s pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company’s lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros'...